International consensus statement on the use of disease-modifying agents in multiple sclerosis
International consensus statement on the use of disease-modifying agents in multiple sclerosis
复制标题
关于使用疾病缓解药物治疗多发性硬化症的国际共识声明
DOI：
10.1191/1352458502ms769oa
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
P Soelberg Sørensen
中科院分区：
文献类型：
--
作者：
M S Freedman;L. Blumhardt;B. Brochet;G. Comi;J H Noseworthy;M. Sandberg;P Soelberg Sørensen
目的：提供在多发性硬化症（MS）治疗中使用疾病调节剂的建议，并确保那些可能受益的患者可以获得治疗。方法：指导委员会准备了共识声明的初稿，并根据一组MS专家的书面意见进行了修改。在随后的一个讲习班上，讨论了协商一致声明的措辞，必要时进行了修改，与会者表示他们使用电子投票系统的支持程度。随后，一份新的声明草案被发送给MS一个更大的国际意见领袖团体，以征求进一步评论。结果：一些声明得到了同意，这些声明概述了考虑MS疾病改善治疗的标准和治疗建议。每项发言都被95%或以上的与会者完全接受，或只有少量保留。结论：随着治疗多发性硬化症的新方法和其他治疗药物的出现，需要定期审查和修改声明。
Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. Results: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.